Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Rangle who wrote (39405)	2/24/2009 9:23:10 AM
From: Rangle	Read Replies (1) \| Respond to of 48461

SIGA Technologies announces the results of non-human primate study suggests ST-246 can be used in combination with small-pox vaccine, and may improve the safety profile of vaccine Co announces the results of a non-human primate study by the Southern Research Institute that suggests that ST-246 can be used in combination with a well-known smallpox vaccine and may improve the safety profile of the vaccine. The study investigated the efficacy of concurrent administration of ST-246, SIGA's smallpox antiviral candidate drug, and Acambis' ACAM2000(tm) smallpox vaccine in non-human primates. When concurrently administered, ST-246 appears to reduce the size and intensity of the lesion formed at the vaccine administration site while the vaccine still confers similar levels of protection in the test animals compared to animals given vaccine alone, based on a subsequent challenge with lethal doses of monkeypox virus. .